Novartis's Kedalion Buy Could Revive Prospects For Xiidra
Dry Eye Drug Struggling Commercially
Getting hold of Kedalion's device that delivers topical drugs to the eye with comparable effect but with up to an 80% reduction in dose compared to standard eye drops bodes well for Novartis's ophthalmology business.
